IMC Chicago
RARE icon

IMC Chicago’s Ultragenyx Pharmaceutical RARE Stock Holding History

IMC Chicago’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$256K Buy
17,000
+7,400
+77% +$178K ﹤0.01% 5439
2026
Q2 		$321K Sell
9,600
-28,500
-75% -$708K ﹤0.01% 5153
2026
Q1 		$798K Buy
38,100
+14,700
+63% +$331K ﹤0.01% 3498
2025
Q4 		$538K Buy
+23,400
New +$770K ﹤0.01% 3422

Other funds holding RARE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

IMC Chicago's RARE Position: Q3 2026 in Review

IMC Chicago increased its Ultragenyx Pharmaceutical (RARE) stake by 426% in Q3 2026, buying an estimated $2.61M and bringing the position to 134,201 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

IMC Chicago first reported a position in RARE in Q4 2025 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • IMC Chicago held 134,201 shares of Ultragenyx Pharmaceutical worth $2.02M as of Q3 2026.
  • IMC Chicago bought 108,666 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $2.61M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #3154 holding.
  • IMC Chicago first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.